• book
    0% of Neoplastic Mimics in Dermatopathology completed

From the Publisher

Virtually all sites in the human body can host lesions that simulate neoplasms, and many of these "pseudotumors" can simulate neoplasms on all levels of analysis-- clinical, radiologic, and pathologic-- thus they represent particular diagnostic pitfalls for the pathologist that can ultimately lead to therapeutic misdirection. This book provides the pathologist with detailed morphologic descriptions and diagnostic guidance in recognizing these neoplastic mimics as they occur in the skin. In addition, descriptions and diagnostic guidance are provided for the range of skin lesions that may mimic benign masses but are in fact neoplastic. This analysis of diagnostic mimics guides the pathologist through recognizing and distinguishing the unusual variants, morphologic anomalies and misleading features that may easily lead to an inaccurate interpretation and missed diagnosis. The book emphasizes imaging and clinical correlations throughout to support the pathologist as consultant to the diagnostic and clinical management team. Every pathologist who sees skin cases will find this book a valuable working tool to ensure accurate diagnosis.
Published: DemosMed on
ISBN: 9781620700129
List price: $160.00
Read on Scribd mobile: iPhone, iPad and Android.
Availability for Neoplastic Mimics in Dermatopathology
With a 30 day free trial you can read online for free
  1. This book can be read on up to 6 mobile devices.

Related Articles

The Atlantic
4 min read

One Patient, Two Cancer DNA Tests, Two Different Results

A couple years ago, Sibel Blau, an oncologist outside of Seattle, was working with the company Guardant Health to test their novel “liquid biopsies” in patients. The idea behind liquid biopsies is both elegant and promising. A doctor takes a blood sample from a patient, and then Guardant looks for tumor DNA floating in the blood, allowing doctors to identify the tumor’s unique mutations and offer a personalized drug regimen—all without an invasive tissue biopsy. Blau was excited to be on board. When that study wrapped up, Blau still had Guardant test kits left over, so she offered some to her
The Atlantic
8 min read

The Long History of Discrimination in Pain Medicine

Pain is sometimes easy to understand. You break your arm, and it hurts. It gets better. It hurts less. But pain can also be incredibly hard to understand. Chronic pain. Pain that lingers long after an injury should have healed. Pain that resists an easy association between injury and hurt. While this kind of “pain without lesion” has long puzzled doctors, the 19th century ushered in a whole new era of controversy, argues the bioethicist Daniel Goldberg in a recent paper, “Pain, objectivity and history: understanding pain stigma.” The era also brings technological developments—“objective” instr
2 min read

Genetic 'Signatures' Help Spot Deadly Cancers

For most patients diagnosed with prostate cancer, the course of action is clear. Some tumors require no immediate treatment. Others can be removed with surgery or radiation. And some require a more aggressive attack. However, for an estimated 30 percent of patients—about 54,000 men in the U.S. every year—the disease is more erratic. Their so-called intermediate-risk tumors could grow slowly or quickly, or may have already sent undetected malignant cells around the body. Diagnostic tests cannot accurately predict which of these tumors will prove harmless or deadly, often leading to excessive or